Halle, Germany

Irene Reichstein

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Imtm Gmbh. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Irene Reichstein. Retrieved from https://idiyas.com/inventor/irene-reichstein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile



Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Irene Reichstein: Innovator in Peptidase Inhibitors

Introduction

Irene Reichstein is a notable inventor based in Halle, Germany. She has made significant contributions to the field of biochemistry, particularly in the development of therapeutic agents. Her work focuses on innovative solutions for treating inflammatory and other diseases.

Latest Patents

Irene holds a patent for "Dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseases." This patent includes compounds of the general formulae (1) A-B-D-B'-A' and (2) A-B-D-E, which represent her innovative approach to drug development.

Career Highlights

Irene is associated with Imtm GmbH, where she continues to advance her research and development efforts. Her work has garnered attention for its potential impact on therapeutic strategies in medicine.

Collaborations

Irene collaborates with esteemed colleagues such as Siegfried Ansorge and Klaus Neubert, contributing to a dynamic research environment that fosters innovation.

Conclusion

Irene Reichstein's contributions to the field of biochemistry and her innovative patent demonstrate her commitment to advancing medical therapies. Her work continues to inspire future developments in the treatment of diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…